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A B S T R A C T
Crack cocaine use is rising in the United Kingdom (UK), with smoking the primary form of administration.
Provision of safe inhalation equipment for crack cocaine is prohibited under UK law. Pipes used for crack cocaine
smoking are often homemade and/or in short supply, exacerbating COVID-19 transmission and respiratory risk.
This is of concern, given high prevalence of respiratory health harms such as chronic obstructive pulmonary
disease (COPD) among people who smoke illegal drugs. This commentary draws on scoping review and mixed
method empirical evidence to argue for provision of safe crack inhalation equipment in the UK, with com-
mensurate legal reform. Review of crack inhalation interventions illustrates the health protective and service
engagement benefits of smoking equipment supply. Survey data generated with 455 people who inject drugs in
London illustrate high prevalence of current crack use (66%, n=299). Qualitative accounts illustrate perceptions
of relative smoking safety – alongside accounts of severe respiratory-related health harms. To date, injecting
drug use has been of primary concern in relation to harm reduction initiatives. It is crucial that people who
smoke illegal drugs are considered a vulnerable population in regard to COVID 19 transmission and fatality risk,
with innovative harm reduction measures scaled up in response.
Introduction
A primary focus of harm reduction research and intervention is
mitigation of injecting-related health harms. Understanding and
working to reduce the health harms associated with drug inhalation
has, in the United Kingdom (UK), been comparatively neglected. It is
crucial to rectify this deficit, particularly in the current COVID-19
context and in relation to crack cocaine (hereafter, 'crack') inhalation.
In the UK very few treatment or harm reduction supports exist for the
high and growing population of people who use crack. Although
smoking is generally considered safer than injecting, legal provision is
only available for injecting equipment distribution. As outlined in this
article, this policy lacuna acts to heighten health harms and exacerbate
COVID-19 vulnerability among an already very marginalised popula-
tion.
The UK has the highest prevalence of people who use crack in the
European region (EMCDDA, 2019). This is a growing population, with
an 8.5% rise from 166,640 in 2012 to 180,748 in 2017 (Hay et al.,
2019) highlighted as a matter of governmental concern (Public Health
England and Home Office, 2019). An offical inquiry into this increase
reports heightened availability, affordability and acceptability of crack,
with expanded and ‘aggressive’ marketing also noted. While the ma-
jority of the increase in use is reported among people who inject drugs
(PWID) and/or who are in receipt of opiate substitution therapy (OST),
samples drawn from treatment and criminal justice services are subject
to bias. Modelling data for 2017 estimate 52,677 people who use crack
but not opiates (Hay et al., 2019). Women appear over-represented in
this population, one that is largely ‘hidden’ from service or research
data capture (Hope, Hickman & Tilling, 2005).
Well evidenced is the effectiveness of OST and needle and syringe
programmes (NSP) in attracting stigmatised populations to services and
reducing blood-borne virus transmission (Larney et al., 2017;
Platt et al., 2018). The UK was an early adopter of this crucial harm
reduction response, acting in 1986 to legalise needle and syringe pro-
vision to prevent an HIV epidemic among PWID. Commensurate action
to protect the health and welfare of people who smoke crack is, how-
ever, stymied by legislative barriers. This commentary draws on mixed-
method data from current research with PWID, coupled with review of
the international academic and grey literature on crack smoking health
impacts and interventions, to explore the case for review of UK policy
pertaining to crack pipe supply. Just as the HIV epidemic provided a
crucible for long needed legislative action regarding needle and syringe
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provision, the COVID-19 pandemic necessitates urgent action to expand
and innovate harm reduction and drug treatment services for the ben-
efit of people who smoke crack cocaine.
Evidencing crack, attending to administration
Cocaine is one of the most widely used illegal drugs worldwide, with
prevalence estimated at 0.4% (18.2 million) among people aged 15-64
(United Nations Office on Drugs and Crime, 2018). Global prevalence
reports provide limited specificity regarding drug form, making it dif-
ficult to ascertain scale of crack cocaine versus powder (hydrochloride)
cocaine use. National surveillance data specifying crack use are often
stymied by sampling basis (recruitment services in the UK offering few
crack-specific supports, for example) and thus likely to under-report
prevalence, with seizure data subject to limitations due to the localised
production of much crack product. Crack can, for example, be prepared
in the home for personal use by heating powder cocaine with a base
such as sodium bicarbonate (baking soda). Those with the economic
and/or social capital to do so1, are less likely to fall within the demo-
graphic commonly associated with crack use and/or come to the at-
tention of drug treatment services.
Limitations in the evidencing of crack use extend to mode of ad-
ministration. Concurrent crack and heroin use are commonly reported
among PWID in North American and UK research data, but mode of
crack administration is not always specified. Given that crack can be
injected (after conversion with an acid to a soluble hydrochloride, see
Harris et al., 2019) the assumption may be that this is the primary
practice or, conversely, if focusing on injection-related health harms,
crack smoking may not be of interest or disclosed. The ‘Care & Prevent’
study provides an example. Survey data, generated with 455 PWID in
London, orientated around understanding injection practices but also
associations between skin and soft tissue infection (SSTI) and the renal
disease, AA amyloidosis (see Harris et al. 2018, for rationale and
methods detail). Renal risk necessitated addition of smoking related
questions (McGowan et al., 2020). These highlighted a higher pre-
valence of current crack use (66%, n=299) than would have been
captured by injecting specific questions alone (45%, n=207). Notably,
mode of administration varied for many – with 92 exclusively smoking
crack, 114 exclusively injecting and 93 combining crack smoking with
injection.
Understanding and evidencing mode of administration is important,
given variability of attendant health harms and needed intervention
response. Crack injection is associated with reuse and sharing of in-
jecting equipment (Del-Rios et al., 2019; Hickman et al., 2007), en-
hancing risk of viral and bacterial infections, such as HIV, hepatitis C
and SSTI (Leyva et al., 2020). Crack smoking is associated with pul-
monary and respiratory problems such as pulmonary oedema and
chronic obstructive pulmonary disease (COPD) (Prudenti et al., 2019;
Reino & Lawson, 1993; Restrepo et al., 2007), but also infections sec-
ondary to sores, burns, or cuts, with some evidence of blood-borne virus
transmission from shared crack pipes (Butler et al., 2017; DeBeck et al.,
2009; Fischer et al., 2008; Macias et al., 2008). The current COVID-19
pandemic casts into stark relief smoking related harms and in doing so
calls into question traditional harm reduction hierarchies of risk. As
noted in a qualitative account below, for some, transitioning away from
smoking to injecting may be a pragmatic response to COVID-19 related
risk.
Smoking related respiratory risk
Reported CODP diagnosis among the C&P participant sample was
14% (n=65). This likely reflects limited diagnosis within this popula-
tion. A UK study providing spirometry testing to 807 drug treatment
clients with similar characteristics to the C&P participants, found that
47% (319) had COPD and, of these, 59% were previously undiagnosed
(Peat et al., 2016, see also Nightingale et al., 2020). Spirometry testing
is not routine or employed at many drug treatment services in the UK
and, as illustrated by C&P qualitative accounts, access to medical care is
infrequent and characterised by delay. Ross spoke of living with severe
respiratory pain for three weeks before ambulatory admission to hos-
pital:
It was awful, it was like someone stabbing me, every time I was
breathing in… Severe pain and then when I'd have a hit of heroin it
would work, it would stop the pain for about 2 minutes and then I'd
be back in pain and then I had a fever and then eventually my
girlfriend phoned the ambulance.
For others, continuing to self-medicate and/or lacking a partner to
call an ambulance, acute respiratory symptoms may not come to
medical attention. Dean, for example, stated: “I can't breathe sometimes, I
struggle to get to the chemists to pick my Methadone up, I get out of breath
and I still haven't been to the hospital for that”. Prolonged delays in
seeking care can compound injury, necessitating lengthy hospital stays:
“I've had collapsed lungs, I was in hospital for about 3 or 4 months with that,
then I had crack lung, I was in hospital for about 4 months for that, smoking
too much crack” (Jeff).
Smoking risk is rarely prioritised in harm reduction interventions,
which predominately orientate around injecting practices. This per-
ception of risk hierarchy is reflected in many accounts, with smoking
framed as the ‘healthier option’: “I don't want to inject anymore… If I can
get a decent, enough blows off of a pipe it's not going to do that much damage
is it” (Ian). Kirsty however, had recently transitioned to injecting after
ten years of smoking crack cocaine, saying: “I can't really smoke it be-
cause my asthma's too bad. That's why I've started doing this [injecting]”.
Participants desired access to safer smoking technologies. Craig who
referred to himself as having “an entrenched smoking habit” said “the
perfect solution for me would be that I could vape my drugs… if I could vape
heroin, I'm happy”. Another participant reported adding crack to tobacco
vaping liquid, with apparent success, but this was an isolated case.
Constrained pipe options, transmission risk
The means by which people smoke crack impact not only re-
spiratory vulnerability but also viral transmission risk. Crack smoking is
associated with high rates of sharing pipes, likely due to limited pipe
availability and the sociability of crack smoking for some (Cheng et al.,
2015; Ivsins et al., 2013). Use of makeshift pipes can exacerbate risk of
lip trauma with blood particles on shared pipes associated with trans-
mission risk for HIV, hepatitis C (Macias et al., 2008; Shannon et al.,
2006; Ward et al., 2000) and tuberculosis (Prangnell et al., 2017). Any
sharing of pipes poses an acute COVID-19 transmission risk, given the
infectivity of the virus. COVID-19 should, however, not be the only
impetus for legislative change. Health harms associated with use of
makeshift pipes are myriad, as illustrated below.
Pipes used in the UK for crack smoking include glass or metal pipes,
often marketed for sale as ornaments, and makeshift or repurposed
implements such as metal soft drink cans, glass bottles, plastic water
bottles, lightbulbs and empty asthma inhalers (see figure 1). Most C&P
participants, if specifying smoking equipment, referred to repurposing
small glass bottles, as Ben describes:
A Martell bottle. So a glass alcohol bottle, a small one. You have to
get, you know the spiky fences - you just hit it on the bottom bit so
then the glass pops through and they've changed the Martell bottles
1 Crack cocaine is generally available in smaller weights and thus lower prices
than powder cocaine. It is able to be consumed immediately, whereas the
‘washing up’ process necessitates time, some expertise and access to a safe
private space.
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now so you can't do it because they realised why people were doing
what they do, so create a hole in the bottom and then you get the
mesh or the metal and you just burn it and then put it into the top
and then you've got a pipe.
Of note here, is the reference to the design of Martell bottles being
changed to prohibit conversion. This is a concern, exacerbating risk of
health harms such as cuts, burns and fume inhalation from use of less
suitable materials such as tin cans and plastic bottles.
Crack pipe choice is primarily determined by availability
(Shehab, 2014; Ti et al., 2011). When safe supply is limited or absent,
health harms are exacerbated. Pipes made from fragile and/or non-heat
resistant glass can break or explode on use, risking cuts and burns; tin
cans or metal pipes can overheat, causing burns to lips, hands and
mouth; broken pipes or materials with sharp edges can cause damage to
the lips and hands; pipes with very short stems can cause respiratory
damage through hot smoke inhalation and nose burns when lit too close
to the face (Leonard et al., 2008; Fischer et al., 2010; Malchy et al.,
2008; Porter et al., 1997; Prangnell, 2017). Use of plastic implements,
such as old asthma inhalers or plastic bottles can partially melt and
cause respiratory damage through fume inhalation (Shehab, 2014;
Ti et al., 2011). Fumes may also be emitted from repurposed tin cans,
with the use of ash as a suspension device exacerbating toxin inhalation
(Carty, 2002; Shehab, 2014). Other materials used as filters or sus-
pension devices include metal screens supplied for cannabis pipes and
pieces cut from stainless steel scouring pads. Scouring pad pieces can
shed loose fibres and/or break apart during use, with particles inhaled
associated with mouth bleeding and respiratory damage (Malchy et al.,
2008; Porter et al., 1997; Prangnell et al., 2017). Metal screens can
come loose on repeated use and be inhaled, as documented in case
reports (Ludwig et al., 1999; Moettus et al., 1998).
Safe inhalation interventions
Safe inhalation kits typically include heat-resistant Pyrex and/or
borosilicate glass pipes, metal filters, rubber mouthpieces and push
sticks for cleaning pipes and collecting crack residue (Haydon &
Fischer, 2005; Malchy et al., 2011; Shehab, 2014; Ti et al., 2011). The
majority of intervention evaluation data stem from Canada where crack
smoking harm reduction and equipment provision is widespread
(Strike and Watson, 2017). Evidenced outcomes include reported re-
ductions in the sharing and/or use of risky crack paraphernalia; in-
creased health risk awareness; improved access to services offering
crack paraphernalia and transitions from injecting to smoking
(Frankeberger et al., 2019; Ivsins et al., 2011; Leonard et al., 2008;
Malchy et al., 2008; O'Byrne & Holmes, 2008; Prangnell et al., 2017).
Reported decreases in pipe sharing appear incremental but sustained
(Haydon & Fischer, 2005), with pipe aquistion through health services
significantly and negatively associated with reporting crack-related
health problems (Prangnell et al., 2017).
Despite evidence of positive impact on service engagement and
health harms, many of the Canadian interventions report the need for
intensive advocacy efforts before and during implementation, with
widespread resistance, including from law enforcement, limiting ca-
pacity (Fischer et al., 2007; Ivsins et al., 2013). These impacts were
differentially experienced and enacted across localities. Toronto ser-
vices, for example, report targeted law enforcement, with crack pipe
confiscations and charges laid against service providers and clients
under the Controlled Drugs and Substances Act. In Vancouver, how-
ever, police issued a statement assuring of the legality of pipe posses-
sion and supply, providing needed reassurance to providers, suppliers
and consumers of safe inhalation interventions (Haydon &
Fischer, 2005). In the UK context, where supply is prohibited, such a
reassurance could be provided through a ‘letter of comfort’ or ‘mem-
orandum of understanding’ between police and service providers. This
would amount to an informally agreed non enforcement approach op-
erating on a local basis - a form of de facto decriminalisation, similar to
tolerance approaches, such refraining from policing near drug services,
that have often preceded formally legislated harm reduction innova-
tions.
Given prohibitions on crack pipe supply, there is a dearth of evi-
dence on associated interventions the UK context. There are indications
of ‘underground’ distribution in some UK locations, including through
secondary supply. It is crucial that these are supported and evidenced,
particularly given the current COVID-19 context. Early initiatives in-
clude the peer-based ‘Crack Squad’, who offered innovative harm re-
duction advice and worked to destigmatise crack use through dispelling
myths regarding inevitable compulsivity and dysfunction (Carty, 2002).
The Crack Squad advocated for the safe and legal supply of crack pipes
and mouthpieces, while also informing on the relative risks and benefits
of alternative options, including homemade pipes. The PIPES (Pro-
moting Inhaled Pleasure Easily and Safely) intervention also aimed to
empower users by informing of the harms and benefits of different
crack smoking devices. Qualitative interviews demonstrated interven-
tion need, with limited knowledge evident about harms associated with
different pipes and cutting agents. Reflecting on PIPES, Shebab (2014)
comments on the frustrations and limitations of providing information
on the health risks of makeshift equipment while legally unable to
supply safe pipes to enable risk reduction.
Irish law differs from that in the UK, in that there is no criminal
provision relating to the supply of equipment for the administration of a
controlled drug. Pipes are distributed through NSP and associated ser-
vices, with a street outreach initiative highlighting the relationship
between pipe acceptability and service engagement. Over a year, seven
pipes were trailed with outreach engagement ebbing and surging ac-
cording to pipe provided. Crack use was not reported to increase during
the intervention, with the following acceptability criteria deemed
Figure 1. Makeshift pipes from bottles.
(All photos provided to the author by people who use crack in the UK)
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essential to maximise service engagement: pipe size and durability
(small, strong and easy to conceal); provision of purpose fit gauze; good
retention of crack residue (enabling reuse, see figure 2); familiarity and
ease of use (does not require a change in smoking technique); and
pleasure (does not diminish drug effect) (O'Heaire, 2013).
Discussion
As with other illegal drugs, crack use crosses social strata, but is
particularly associated with poverty, homelessness, incarceration, and
limited access to or uptake of health and social services (Butler et al.,
2017; Fischer et al., 2015; Ivsins et al., 2013). A dearth of crack-specific
treatment and harm reduction services exacerbates social margin-
alisation. Despite the evidenced potential for safe inhalation interven-
tions to reduce harms, including through promoting transitions from
injecting, resistance to implementation has been widespread. In the UK
this takes the form of legal prohibition, stymieing service provision and
needed context-specific intervention development and evaluation re-
search. The evidence for respiratory and viral transmission harms from
unsafe crack pipe use is, however, irrefutable. The COVID-19 pandemic
puts these risks in sharp relief and offers a window of opportunity for
needed change.
The British Medical Journal hosts a dedicated blog to COVID-19 and
smoking related harms. Here Barnsley & Singh Sohal (2020) call for
research attention and funding to be given to the role of smoking in the
contraction, transmission and mortality rate of Covid-19, with
budget allocation to health stimulus packages, scientific research, and
actions to further reduce smoking rates. They refer to tobacco smoking,
an easily measured and relatively widespread practice, of epidemiolo-
gical significance in mapping COVID-19 transmission and fatality risk.
While publication on the interplay between COVID-19 risk and tobacco
smoking abound (eg. Cai, 2020; Vardavas & Nikitara, 2020), com-
mensurate attention to marginalised populations who smoke illegal
drugs (most of whom also smoke tobacco) is limited. Kalan et al. (2020)
stress the potential of waterpipe (hookah) tobacco smoking to facilitate
COVID-19 transmission, given the common practice of sharing water-
pipes (albeit with disposable mouthpieces). Sharing of crack pipes,
often homemade and offering limited respiratory and transmission
protection, is arguably of greater concern.
Provision of OST and sterile injecting equipment is evidenced to
have saved countless lives – not only through directly averting hepatitis
and HIV transmission but indirectly, though providing links to ancillary
health and social care services. While OST offers protection against
heroin withdrawal, there is no commensurate pharmaceutical treat-
ment available for crack use. While people with COPD are recognised as
a COVID-19 vulnerable population, entitled to receive assistance such
as medication delivery to self-isolate, respiratory conditions are likely
underdiagnosed among people who smoke illegal drugs. This has im-
plications for the ability and will to enact protective practices, parti-
cularly in the absence of well-established pharmacological supports for
stimulant dependency. NSP in the UK offers few options for people who
smoke illegal drugs, apart from the recent provision of foil to capacitate
heroin inhalation. The limited reach and relevance of extant treatment
services for people who use crack is recognised at a governmental level,
with an associated call for research on how to best engage those
‘hidden’ from service access (Public Health England & Home
Office, 2019).
North America provides an example of where to start. While crack
pipes are supplied in many European countries, Canada offers a com-
parative wealth of published evidence on safe inhalation intervention
implementation and impact. Outcome measures generally pertain to
pipe sharing practices, service engagement and health impacts such as
BBV transmission. Reductions in risk practices and positive health im-
pacts are evidenced (Pragnell et al., 2017), with increased pipe avail-
ability supporting service engagement, also transitions away from drug
injecting (Leonard et al., 2008). The Irish outreach intervention report
(O'Heaire, 2013) illustrates not only the importance of availability but
pipe acceptability for enhancing engagement and uptake. This is one of
the few studies to detail the pragmatics and pleasures important to
people who smoke crack when considering a pipe. Residue collection
potential, for example, is rarely mentioned in the published literature –
yet crucial when considering economies of use (Porter et al., 1997).
Some pipes will retain crack residue better than others, enabling reuse
and potentially diminishing urgency of the next purchase. Makeshift
smoking implements such as crushed tin cans are not only harmful to
health, but do not enable residue collection and reuse (Shehab, 2014).
Motivation to use safe inhalation devices is likely to be high among
people who smoke crack in the UK, particularly if accompanied by peer-
disseminated information on their pleasurable and pragmatic benefits.
A high proportion of London PWID participants report both current
crack injection and smoking. Provision of acceptable pipes may be in-
strumental in further facilitating transitions away from injecting.
Current UK law prohibits supply of crack pipes and related para-
phernalia under section 9A of the Misuse of Drugs Act 1971. Prior to
1986, provision of any injecting equipment was prohibited, with early
drug user networks and some service providers contravening the law in
recognition of the serious risk posed to their communities by the HIV/
AIDS epidemic. In 1986, the Thatcher Government acted to avert the
spread of HIV by inserting section 9A into the Misuse of Drugs Act. This
allowed for the legal provision of hypodermic syringes but explicitly
prohibited supply of any other injecting or drug use equipment. Covert
supply of paraphernalia was enacted by some providers to facilitate safe
injecting and reduce health harms. Citric acid provision, for example,
offers safe alternative to use of lemon juice (associated with serious
candidal eye infections) in injection preparation. The first letter of
comfort for injecting paraphernalia appears to have been negotiated
with the Dorset Police Constabulary in the late 1990s to protect pro-
viders from prosecution under the Misuse of Drugs Act for citric acid
supply. In 2003 provision of citric and other injecting paraphernalia
items (filters, water, cookers) were legalised as exceptions to Section
9A. The most recent addition to these exceptions was in 2014, when
after four years of campaigning and a prolonged legislative process,
Figure 2. Glass pipes using stainless steel suspension devices, with crack and residue.
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provision of foil was permitted to encourage people to smoke heroin
rather than inject (Exchange Supplies, 2018).
Amendments to Section A of the Misuse of Drugs Act 1971 can take
years to enact. Pursuing this legislative process for provision of safe
inhalation equipment will take too long to impact COVID-19 related
risks. In March 2020, the author and others made a ‘letter of comfort’
for crack pipe provision request. If granted, this would give assurance to
providers that they could supply crack pipes without prosecution. The
case was made, as in this paper, that safe inhalation equipment provi-
sion could reduce COVID-19 transmission and fatality risk. While sup-
ported by members of the police force, this request was refused at the
Home Office level. Given the urgency of the situation, and a raft of
other measures taken to reduce harm among the most vulnerable – such
as unprecedented flexibility in OST prescribing – this refusal is con-
cerning. It is indicative, perhaps, of the particularly vilified status of
crack cocaine and its use. Demonstrating the ‘moral sidestep’ in drug
policy at play (Stevens, 2019), concerns about ‘liberalisation of drug
use’ were called on to sidestep evidence for reductions in health harms.
The provision of injecting equipment is well evidenced to have
prevented viral transmission and saved lives (Larney et al., 2017;
Platt et al., 2018). Given the lacuna in care provisions for people who
smoke crack, it is timely to turn to the early days of the HIV academic
and learn from the actions that initiated legal reform of injecting
equipment provision. North American users responded to the rise of
HIV/AIDs among their community in the late ‘70s with the under-
ground distribution of needles and syringes; Junkiebond, a Netherlands
user collective, pioneered peer-led needle exchange in the early 80s
(Friedman et al., 2007). Innovation requires courage – potentially
acting outside the law to protect the health of marginalised commu-
nities while advocating for legal reform. Urgency, such as we are faced
with in this current pandemic precludes negotiation of lengthy legal
procedures. Harms adverted by swift action, albeit risky, can strengthen
advocacy claims for legislative change.
Conclusion
In the current COVID-19 context, people who use drugs face unique
needs and risks … the COVID-19 pandemic requires countries to take
extraordinary measures to protect the health and well-being of the
population. (Pūras, 2020)
Dainius Pūras, the United Nations Expert on the Right to Health,
calls for countries to take courage and enact extraordinary measures to
protect the health of their citizens. Provision of safe inhalation devices
for people who smoke crack cocaine is not, however, an extraordinary
measure. This simple and cost-effective intervention is evidenced to
reduce health harms and provide a link to services for a largely dis-
enfranchised population. Refusal by the Home Office to countenance
this action calls into question the presumed ‘citizenship’ of those whose
health it would protect. Crack use remains uniquely demonised; en-
acted stigma and internalised shame can exacerbate harmful use and
preclude service engagement. It is imperative that services are offered
reassurance so that they can offer purpose-made pipes and mouthpieces
to people who smoke crack. This is crucial to help reduce COVID-19
infection, adverse outcomes and other respiratory-based health harms
for this marginalised population. More broadly, safe inhalation in-
itiatives provide a point of connection for a high risk, largely disen-
franchised population and, through this recognition, can act to diminish
shame and foster wellbeing.
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